ARA-290
Human clinical research for neuropathy/inflammation; Not broadly approved
Brief Overview: ARA-290, also called cibinetide, is engineered from erythropoietin biology but is designed not to increase red blood cell production. Its intended target is the innate repair receptor, which is upregulated during tissue stress and injury. Evidence lens: This is one of the more clinically grounded experimental entries because small human studies exist in neuropathic and inflammatory conditions. Still, the evidence is condition-specific. Improvement in small fiber neuropathy does not automatically prove benefit for every inflammatory or “recovery” use case. How to read this: if you're new, the key distinction is EPO-like origin without the classic EPO red-blood-cell effect. Once you're past the basics, separate plasma half-life from biological signaling duration: the peptide may clear quickly while receptor-triggered repair signaling lasts longer.
- ARA-290 is a synthetic 11-amino acid peptide derived from the structure of Erythropoietin (EPO).
- However, it is specifically designed to be “non-erythropoietic,” meaning it does not stimulate red blood cell production.
- Instead, it is a selective agonist for the Innate Repair Receptor (IRR).
- It is classified as a powerful anti-inflammatory and neuroprotective agent.
- ARA-290, also called cibinetide in development contexts, is an EPO-derived peptide designed to activate tissue-protective signaling without classical erythropoietic stimulation.
ARA-290 targets the body’s primary “distress” signaling system to shut down chronic inflammation and initiate repair:
- Selective IRR Binding: In the presence of tissue injury or metabolic stress, the body expresses the Innate Repair Receptor (a complex of the EPO receptor and the beta-common receptor). ARA-290 binds to this specific heteromer.
- Inflammation Suppression: Once bound, it inhibits the production of pro-inflammatory cytokines (like TNF-alpha and IL-6) and prevents the activation of the “inflammasome.” Small-fiber neuropathy research: ARA-290/cibinetide has been studied in sarcoidosis-associated small-fiber neuropathy and painful diabetic neuropathy, including corneal and skin small-fiber endpoints. This supports an investigational nerve-repair rationale, not a guaranteed or unique ability to repair small-fiber neuropathy.
- Apoptosis Prevention: It protects cells from “programmed cell death” triggered by ischemia (lack of oxygen) or oxidative stress.
- The key mechanism frame is innate repair receptor/tissue-protective signaling, including anti-inflammatory and neuroprotective pathways. It is not a general nerve-regeneration guarantee. The mechanism here is a plausibility map, not proof of a clinical outcome.
- ARA-290/cibinetide has selected clinical research in sarcoidosis-associated small-fiber neuropathy and painful diabetic neuropathy.
- Diabetes/metabolic findings are small-study exploratory signals, not established metabolic treatment.
- The 2026 lupus brain-fog report involves EG501, not ARA-290/cibinetide.
- Wound-healing claims remain preclinical/adjacent unless a specific human wound-healing study is cited.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions.
- Protocol 1: Clinical/SFN Protocol [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 4 mg – 10 mg; Frequency: Once daily; Duration: 28 to 30 days; Titration/loading: The "Clinical Loading": successful neuropathy trials used higher doses (10 mg daily) for 4 weeks.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: General Repair Protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 1 mg – 4 mg; Frequency: Once daily; Duration: 14 to 28 days; Titration/loading: After an initial cycle, some users move to a maintenance dose of 2 mg twice weekly.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Trial-style SC dosing and research-market extrapolations are different things. Dosing decisions are usually tied to neuropathic-symptom endpoints, not acute performance or cosmetic goals. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: about 10-100 minutes by the 5-half-life rule.
- Half-life basis: Few minutes to about 20 minutes depending route and source. The repair signal may outlast plasma exposure, so this estimate applies to plasma concentration, not duration of biological effect.
- Beginner translation: This estimate uses the standard four-to-five-half-life convention. It describes when plasma exposure would be expected to approach a plateau during repeated dosing, not when the desired outcome is complete.
- Half-life: Very short systemically (estimated <2 minutes).
- Biological Duration: Despite leaving the blood rapidly, the “switch” it flips on the Innate Repair Receptor triggers a cellular signaling cascade that lasts for 24 hours or longer.
- Stability: The lyophilized powder is relatively stable but should be refrigerated once reconstituted with Bacteriostatic Water.
- ARA-290 has a short plasma half-life, yet effects may be assessed through downstream symptom or tissue-protection markers. Short exposure does not automatically mean frequent redosing is beneficial. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- BPC-157: Often stacked for systemic “healing” protocols, as BPC-157 focuses on growth factors while ARA-290 focuses on the inflammatory “off-switch.” Cerebrolysin: Combined in 2026 protocols for neurodegenerative recovery to address both nerve growth (Cere) and nerve inflammation (ARA).
- NAD+: To provide the energy required for the nerve regeneration processes stimulated by ARA-290.
- It is commonly discussed with mitochondrial, anti-inflammatory, or neuropathy-support stacks. Avoid combining many anti-inflammatory agents if the research goal is to understand a single signal. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Side Effects: Generally well tolerated in the small clinical trials to date, though long-term safety is not established. In human trials, side effects were nearly identical to the placebo group. Occasionally, users report a mild “flushing” sensation or injection site redness.
- No Polycythemia Risk: Unlike EPO, ARA-290 does not increase red blood cell counts or thicken the blood, which removes EPO’s blood-thickening risk; This is not the same as proven cardiovascular safety, which has not been established for this investigational peptide.
- Contraindications: Pregnancy and breastfeeding (due to lack of data).
- Major practical concerns are injection-site effects, immune reactions, uncertain long-term outcomes, and disease-context mismatch. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Pain Scales: Tracking levels of neuropathic pain (burning, tingling, numbness).
- Skin Biopsy: In clinical settings, “Skin Nerve Fiber Density” tests are the gold standard for measuring success.
- Inflammatory Markers: Monitoring hs-CRP and ESR to track the systemic reduction in inflammation.
- Useful monitoring includes neuropathic pain scores, small-fiber/autonomic markers when available, glucose control if diabetic neuropathy is involved, CBC, inflammatory markers, and adverse-event diary. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Currently has Orphan Drug Designation for the treatment of Sarcoidosis-associated neuropathy but is not yet approved for general use.
- WADA: Not currently on the prohibited list (since it does not increase red blood cell production), though it is often scrutinized due to its relation to EPO.
- Availability: Widely available as a “research chemical.”
- ARA-290/cibinetide is investigational and not a general FDA-approved peptide therapy. Trial references are separate from research-market product claims. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.